AAV9-mediated erythropoietin gene delivery into the brain protects nigral dopaminergic neurons in a rat model of Parkinson's disease.
about
Structural Insight into the Unique Properties of Adeno-Associated Virus Serotype 9Systemic injection of AAV9-GDNF provides modest functional improvements in the SOD1G93A ALS rat but has adverse side effects.Erythropoietin improves neurobehavior by reducing dopaminergic neuron loss in a 6‑hydroxydopamine‑induced rat modelGene delivery with viral vectors for cerebrovascular diseases.Pre-immunization with an intramuscular injection of AAV9-human erythropoietin vectors reduces the vector-mediated transduction following re-administration in rat brainIsoforms of the Erythropoietin receptor in dopaminergic neurons of the Substantia Nigra.Pseudotyped adeno-associated virus 2/9-delivered CCL11 shRNA alleviates lung inflammation in an allergen-sensitized mouse model.Alleviation of lung inflammatory responses by adeno-associated virus 2/9 vector carrying CC10 in OVA-sensitized miceImmunologic privilege in the central nervous system and the blood-brain barrier.Vascular growth factors in neuropsychiatry.Axonal degeneration as a therapeutic target in the CNS.The advent of AAV9 expands applications for brain and spinal cord gene delivery.A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting.Targeting erythropoietin for chronic neurodegenerative diseases.Gene therapy for Parkinson's disease: state-of-the-art treatments for neurodegenerative disease.Synthetic nucleic acids delivered by exosomes: a potential therapeutic for generelated metabolic brain diseases.Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of Alzheimer's and Parkinson's disease.Intranasal gene delivery for treating Parkinson's disease: overcoming the blood-brain barrier.Towards a Better Treatment Option for Parkinson's Disease: A Review of Adult Neurogenesis.Erythropoietin mediates brain-vascular-kidney crosstalk and may be a treatment target for pulmonary and resistant essential hypertension.Transfection of primary brain capillary endothelial cells for protein synthesis and secretion of recombinant erythropoietin: a strategy to enable protein delivery to the brain.Generation and characterization of anti-Adeno-associated virus serotype 8 (AAV8) and anti-AAV9 monoclonal antibodies.Erythropoietin reduces apoptosis of brain tissue cells in rats after cerebral ischemia/reperfusion injury: a characteristic analysis using magnetic resonance imaging.Gene therapy for Parkinson's disease
P2860
Q27678476-03AC3B16-D327-4A20-806F-D18D53A4EF51Q33600773-A7A02264-428B-4353-8C43-AAD7ECD99DC6Q33890267-6491E354-773F-4372-A167-D0603805959DQ33917592-19AD0B34-B65D-4BBF-98E8-2069FDB74A06Q34718452-6F204110-11A8-4898-B6F2-5527C9FE2884Q36094360-B2E9770F-4FD7-486B-8BFD-E964F0AB29E1Q36401352-772FAC6A-5B21-4A18-868D-7A16664509C4Q36562646-7EE2EAD1-12AF-4C4B-9460-ABB2181E0A08Q36684162-DB6EBB82-AFB9-4BA6-92B2-E2E95C37E9CCQ37633688-DBCF2EF2-7E33-441A-9F4F-DE0F79CADF78Q37990880-F0613034-AC05-4FA5-9786-2D9A9EDB9CF8Q38004089-0A13138D-F7D7-4163-815A-1EE361419869Q38075068-D09104C6-00AC-4FDF-B5DE-95124C3996E2Q38091151-807EB04D-0D77-4331-893F-ABBB71B76FCCQ38112216-FBB2E0E8-EBC5-4C83-98AB-43C0CCB05242Q38136096-0AEB9BA6-248F-465C-A351-9144C9EBF38EQ38303586-17D9A553-11A3-450D-81BC-3526E3FB9378Q38569775-067ADBC0-6962-4177-9C44-478FD5974E23Q38950746-5BFC3A7E-AA14-4706-BC97-C5C9D5E770EFQ39266683-36366765-1B31-4126-BBFE-26DF70653A0DQ40292313-5FE9BB6C-9231-4393-8F94-596188091402Q40611143-F2F40B5A-F181-4CA9-8180-D6AA16C99CA0Q41647851-309DEE32-EBE6-42A0-AE0E-0666D91AE1D2Q58913419-A21739E5-E63A-4093-96D1-F139D1A5E41D
P2860
AAV9-mediated erythropoietin gene delivery into the brain protects nigral dopaminergic neurons in a rat model of Parkinson's disease.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
AAV9-mediated erythropoietin g ...... model of Parkinson's disease.
@en
AAV9-mediated erythropoietin g ...... model of Parkinson's disease.
@nl
type
label
AAV9-mediated erythropoietin g ...... model of Parkinson's disease.
@en
AAV9-mediated erythropoietin g ...... model of Parkinson's disease.
@nl
prefLabel
AAV9-mediated erythropoietin g ...... model of Parkinson's disease.
@en
AAV9-mediated erythropoietin g ...... model of Parkinson's disease.
@nl
P2093
P2860
P921
P356
P1433
P1476
AAV9-mediated erythropoietin g ...... model of Parkinson's disease.
@en
P2093
P2860
P2888
P356
10.1038/GT.2009.113
P577
2009-09-03T00:00:00Z
P5875
P6179
1002004424